We are dedicated to providing outstanding customer service and being reachable at all times.
Chromatin-associated RNA–DNA interactions followed by paired-end-tag sequencing (ChRD-PET) offers a new dimension in 3D genomic analysis.
At CD Genomics, we provide an end-to-end ChRD-PET sequencing service that reveals how coding and noncoding RNAs shape chromatin structure and transcriptional regulation.
Our comprehensive workflow—from sample preparation and chromatin immunoprecipitation (ChIP) to sequencing and advanced bioinformatics—helps researchers explore promoter-centered, enhancer-linked, and R-loop-derived RNA–DNA interactions with high precision.
We help clients:
At a glance:
Chromatin-associated RNA–DNA interactions followed by Paired-End Tag sequencing (ChRD-PET) is a cutting-edge technique designed to map how RNAs physically interact with chromatin across the genome. In this workflow, chromatin complexes enriched by specific antibodies (such as H3 or H3K4me3) are ligated using a biotin-labelled DNA bridge linker to spatially adjacent RNA and DNA molecules. The resulting ligated RNA–DNA fragments are sequenced via paired-end sequencing, enabling detection of RNA–DNA contacts with high specificity and resolution.
Originally developed in rice (ChRD-PET was first described in Nature Plants) the method revealed three classes of RNA–DNA interaction: local (cis), proximal (nearby) and distal (often trans-chromosomal).
Why this matters for 3D genome sequencing and functional genomics:
By integrating with complementary platforms (such as our 3D genome tools), clients can gain a holistic view of genome regulation—from sequence to structure to RNA.
In our CRO service offering, the ChRD-PET platform is ideal for researchers, academic institutions, biotech and pharma teams who aim to:
ChRD-PET combines chromatin immunoprecipitation (ChIP), spatial ligation, and paired-end sequencing to capture chromatin-associated RNA–DNA interactions with high specificity. The process follows a clear, reproducible pipeline optimised for 3D genomic analysis.
Cells or tissues are fixed with formaldehyde to preserve native RNA–DNA–protein interactions within the nucleus. This ensures spatial relationships between chromatin and RNA are retained during extraction.
Antibodies specific to histone marks or chromatin-bound proteins (e.g., H3, H3K4me3) selectively enrich target regions. This step defines the genomic context—promoters, enhancers, or specific regulatory domains—where RNA-DNA interactions are captured.
A biotin-labelled DNA bridge linker is introduced to join spatially adjacent RNA and DNA molecules. This unique ligation design eliminates random contact artefacts and enables high-confidence mapping of RNA–DNA proximity events.
Crosslinks are reversed, and RNA–DNA chimeric fragments are purified. Only ligated RNA–DNA molecules are retained for sequencing, improving specificity and downstream analysis accuracy.
The ligated complexes are converted into sequencing libraries and processed on Illumina or comparable high-throughput platforms. Paired-end sequencing enables precise detection of both RNA and DNA tags in each interaction pair.
Our analytical pipeline aligns paired tags to the reference genome, identifies interaction pairs, and visualises promoter–enhancer networks. Integration with R-loop and chromatin-loop data reveals multi-layered 3D genome organisation.
Together, these steps allow single-molecule-resolution profiling of RNA–DNA interactions, providing essential insights into transcriptional regulation and chromatin topology.
ChRD-PET detects low-abundance chromatin-associated RNAs (caRNAs) and distinguishes true RNA–DNA interactions from random ligations. The use of a biotin-labelled bridge linker and stringent immunoprecipitation reduces background noise, producing high-confidence interaction maps.
Each paired-end tag represents one RNA–DNA contact event. This direct-read strategy provides quantitative, molecule-level insight into transcriptional regulation and RNA-mediated chromatin organisation.
The platform precisely identifies RNA–DNA interactions associated with active promoter and enhancer regions (e.g., H3K4me3-marked sites). It enables researchers to examine how RNAs regulate nearby and distant genes across chromatin loops.
ChRD-PET supports the identification of R-loop–derived RNA–DNA hybrids and the classification of noncoding RNAs (lncRNAs, snoRNAs, miRNAs) involved in chromatin regulation. This expands understanding beyond coding RNAs to the full regulatory RNA landscape.
The resulting datasets align seamlessly with ChIA-PET, HiChIP, and Pore-C. Combined analyses link RNA–DNA contacts with DNA–DNA and protein–DNA interactions for a multi-layered 3D genomic model.
Validated for plant tissues and adaptable to animal or microbial systems, the method accommodates diverse biological contexts in functional genomics, crop improvement, and molecular breeding research.
ChRD-PET enables precise localisation of RNA–DNA contacts near active promoters and enhancers, helping researchers uncover how chromatin-associated RNAs influence transcription initiation and enhancer looping. This is essential for studying gene activation networks in plants and other eukaryotes.
By combining chromatin immunoprecipitation with sequencing, ChRD-PET reveals how RNAs interact with histone-modified regions such as H3K4me3 or H3K27ac. These data clarify how epigenetic modifications and RNA molecules cooperatively regulate gene accessibility.
The method profiles RNA–DNA hybrids derived from R-loops and classifies noncoding RNAs—including lncRNAs, snoRNAs and miRNAs—that anchor chromatin interactions. This insight supports studies on RNA-driven genome stability and chromatin organisation.
Integrated with 3D genome sequencing platforms such as ChIA-PET, HiChIP, and Pore-C, ChRD-PET provides promoter-to-enhancer interaction maps that connect RNA–DNA signals with chromatin loops and domains.
ChRD-PET supports comparative transcriptome studies, revealing how regulatory RNAs shape gene networks across developmental stages or environmental conditions. In agriculture, it offers tools to explore RNA-mediated chromatin regulation underlying stress response and yield traits.
| Tier | Analysis Modules | Description |
| Basic Analysis | Read Quality & Pre-processing | Adapter trimming, quality filtering, removal of low-confidence reads; QC report. |
| Alignment to Reference Genome | Map paired RNA–DNA tags to genome; output aligned BAM files and mapping statistics. | |
| Interaction Pair Assignment | Identify valid RNA–DNA tag pairs, classify into cis, proximal, distal contacts. | |
| Peak Detection & Annotation | Detect enriched DNA regions (promoters/enhancers), annotate interacting RNAs with gene context. | |
| Advanced Analysis | R-Loop & Non-coding RNA Characterisation | Integrate R-loop data, classify lncRNAs/snoRNAs/miRNAs engaging chromatin; deliver hybrid lists. |
| 3D Genome Integration | Combine with loop data from ChIA-PET, HiChIP or Pore-C; visualise RNA–DNA in chromatin topology. | |
| Interaction Network & Quantification | Build network models of RNA–DNA contacts, quantify interaction frequencies, generate heatmaps. | |
| Visual Reporting & Browser Tracks | Provide BEDPE tables, IGV/UCSC browser tracks, circular genome plots and publication-ready figures. |
This comprehensive workflow enables multi-layered insights into how RNAs shape genome organisation and gene expression, giving researchers an integrative view of chromatin structure and function.
| Sample Type | Recommended Input | Minimum Acceptable | Quality Metrics (Pre-QC) |
| Fresh plant tissue / cell culture | ≥ 10 million cells or ~50 mg fresh tissue | ≥ 5 million cells or ~25 mg tissue | OD₆₀₀/₄₈₀ for intact cells; minimal debris |
| Tissue with histone-antibody target (e.g., H3K4me3) | ≥ 100 µg chromatin equivalent | ≥ 50 µg chromatin equivalent | Chromatin fragment size ~200–500 bp after sonication |
| Crosslinked samples | Standard 1% formaldehyde ×10 min | Use ≤ 1% ×15 min if plant cell wall thick | No excessive cross-linking (DNA smear <500 bp) |
| RNA co-isolated sample (for R-loop or RNA mapping) | ≥ 1 µg total RNA, RIN ≥ 7 | ≥ 500 ng RNA, RIN ≥ 6 | A260/280 = 1.8–2.2; A260/230 ≥ 2.0 |
| Antibody-validated target (ChIP enrichment) | Verified antibody + pre-test pull-down | Dependent on pre-test result | Enrichment fold ≥ 10× vs input |
Shipping & storage guidelines:
Follow regulatory and biosafety shipping guidelines (appropriate carrier e.g., FedEx, DHL).
QC thresholds employed by CD Genomics:
ChRD-PET (chromatin-associated RNA–DNA interactions followed by paired-end-tag sequencing) specifically maps contacts between RNAs and DNA in the context of chromatin, unlike classical 3D genome methods (such as Hi-C) that only detect DNA–DNA contacts; by combining ChIP-based enrichment, RNA-DNA linker ligation and paired-end sequencing, it reveals the RNA dimension of genome architecture.
ChRD-PET is suitable for fresh or frozen cell and tissue samples (plants, animals or microbes) where chromatin-associated RNAs are implicated. It is particularly effective for research on promoter/enhancer interactions, R-loops, noncoding RNAs, transcription-chromatin coupling and 3D genome topology in functional genomics, crop breeding and drug development.
Deliverables typically include raw FASTQ files, processed BEDPE interaction tables, interaction contact matrices, annotated RNA-DNA hybrid lists, browser tracks for IGV/UCSC, circular genome interaction plots and a summary report with metrics, all enabling downstream functional and structural analysis.
Yes. ChRD-PET is fully compatible with platforms such as ChIA-PET, HiChIP and Pore-C. Integration enables multi-layered analysis of RNA–DNA contacts, protein-DNA or DNA–DNA loops, and chromatin domain structures, thereby providing a holistic 3D genomic interaction landscape.
Quality control metrics include: mapping rate to the reference genome (typically ≥ 70 %), unique paired-end tags counts, duplication rate (low duplicates preferred), and cis-/trans-contact ratios reflecting local vs distal interactions (e.g., ~35-40 % local, ~50-60 % distal as seen in published datasets).
Reference
For research purposes only, not intended for personal diagnosis, clinical testing, or health assessment